GLP‑1s: not just weight loss

Glucagon-like peptide 1 drugs were sold to many patients as weight-loss shots, but doctors are increasingly treating them as medicines that can help the heart, liver and sleep apnea even when the scale barely moves. (ksl.com) Clinical trials suggest about 10% to 15% of people who take drugs such as Wegovy and Zepbound do not have substantial weight loss, according to reporting published April 15. The same report said newer research is finding benefits beyond weight change, including reduced inflammation and better heart and liver outcomes. (ksl.com) The clearest evidence came from the SELECT trial, a 17,604-patient study published in the New England Journal of Medicine in November 2023. Patients with obesity or overweight and prior cardiovascular disease who got semaglutide had major cardiovascular events in 6.5% of cases, versus 8.0% with placebo, over a mean 39.8 months of follow-up. (nejm.org) Regulators have also started approving these drugs for conditions other than weight loss. On December 20, 2024, the Food and Drug Administration approved Zepbound for moderate to severe obstructive sleep apnea in adults with obesity, the first drug cleared for that use. (fda.gov) Guidelines are shifting with the evidence. The American Diabetes Association said in its December 9, 2024 Standards of Care update that it added guidance on glucagon-like peptide 1 receptor agonists beyond weight loss for heart and kidney health benefits. (diabetes.org) That medical expansion is colliding with the way many health plans still pay for the drugs. Employers and insurers often cover diabetes treatment more readily than obesity treatment, even as the same medicines pick up more approved uses and more patients ask for them. (nbcnews.com) The cost pressure is large enough that some employers are tightening access instead of broadening it. Jefferson, a Philadelphia-based nonprofit health system with 65,000 employees, said prescription drugs rose from about 14% of its insurance spending a decade ago to 40% last year, and its insurance arm lost about $180 million in 2025, with about one-third tied to glucagon-like peptide 1 coverage. (nbcnews.com) Jefferson now requires employees to complete diet and lifestyle programs before its plan will cover weight-loss glucagon-like peptide 1 drugs, a step Chief Executive Officer Joseph Cacchione said has already saved $20 million this year. NBC News reported list prices of $1,349 a month for Wegovy and $1,086 for Zepbound, while Blue Cross Blue Shield estimated net employer costs at $617 to $766 a month per employee. (nbcnews.com) National employer data shows the same push and pull. KFF said in its 2025 Employer Health Benefits Survey that family premiums reached $26,993, up 6% from 2024, and that larger employers increased coverage of glucagon-like peptide 1 drugs for weight loss while also voicing concerns about utilization and cost. (kff.org) Drugmakers say lower prices and broader coverage can coexist. NBC News reported that Eli Lilly said it is trying to win more employer coverage with a new program for people with job-based insurance, while Novo Nordisk said it plans to cut Wegovy’s list price in 2027 to $675. (nbcnews.com) The result is a messy split-screen in 2026: the evidence base for glucagon-like peptide 1 drugs keeps widening, while the fight over who pays for them is getting narrower and more expensive. (ksl.com)